← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $619B	2,765	0	0%	$253B
2	2 Pfizer PFE $169B	2,391	-13	-0.5%	$173B
3	3 Merck MRK $369B	2,293	+42	+2%	$164B
4	4 AbbVie ABBV $509B	2,034	-29	-1%	$83B
5	5 Amgen AMGN $238B	1,887	-5	-0.3%	$91.1B
6	6 Bristol-Myers Squibb BMY $125B	1,814	+48	+3%	$61.6B
7	7 Gilead Sciences GILD $197B	1,493	-5	-0.3%	$66.4B
8	8 Novartis NVS $288B	1,134	+46	+4%	$26.2B
9	9 GSK GSK $99.1B	848	+48	+6%	$11.7B
10	10 Regeneron Pharmaceuticals REGN $82.8B	719	+48	+7%	$30.4B
11	11 AstraZeneca AZN $261B	562	+4	+0.7%	$19.4B
12	12 Incyte INCY $23B	519	+65	+14%	$16.9B
13	13 Jazz Pharmaceuticals JAZZ $14B	427	+10	+2%	$7.37B
14	14 DELISTED Exact Sciences EXAS	424	+54	+15%	$9.77B
15	15 Takeda Pharmaceutical TAK $63.1B	390	+297	+319%	$3.65B
16	16 Exelixis EXEL $15.5B	378	+33	+10%	$5.7B
17	SGEN 17 DELISTED Seagen Inc. Common Stock SGEN	348	+40	+13%	$11.9B
18	18 Myriad Genetics MYGN $418M	262	-2	-0.8%	$2.62B
19	19 Qiagen QGEN $9.58B	262	+10	+4%	$5.86B
20	20 NeoGenomics NEO $2.19B	235	+25	+12%	$1.65B
21	21 Kyntra Bio KYNB $22.8M	225	+24	+12%	$3.15B
22	22 DELISTED Immunogen Inc IMGN	212	+12	+6%	$320M
23	23 DELISTED Blueprint Medicines BPMC	203	+41	+25%	$3.89B
24	24 Halozyme HALO $13.8B	201	+6	+3%	$1.95B
25	25 Opko Health OPK $1.2B	201	-1	-0.5%	$419M